Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- AHA 2024
Perspectives on CKM syndrome
Javed Butler, MD
Shawna Nesbitt, MD
Muthiah Vaduganathan, MD
- ESC Congress 2024
Effects of empaglifozin on kidney outcomes after acute MI
Deepak Bhatt, MD